骨桥蛋白表达与卵巢癌紫杉醇耐药相关性临床研究

发布时间：2018-03-24 23:05

  本文选题：骨桥蛋白　切入点：卵巢癌　出处：《中国妇产科临床杂志》2015年06期

【摘要】：目的探讨骨桥蛋白(osteopontin,OPN)与卵巢癌紫杉醇化疗耐药的关系及临床意义。方法收集北京市多家三甲医院2013年3月至10月卵巢上皮癌组织72例,根据三磷酸腺苷肿瘤体外药物敏感性检测(ATP-TCA)结果将其分为紫杉醇敏感组(49例)、中度敏感组(15例)和耐药组(8例)。采用免疫印迹法检测各组OPN的表达。结果 1耐药组OPN的表达(2.027±0.402)显著高于敏感组(0.603±0.271)及轻度敏感组(1.173±0.350),三组比较,差异有统计学意义(P=0.000),且其表达与紫杉醇敏感度系数(SI)呈正相关(r=0.459,P=0.000);2 OPN在Ⅲ期卵巢癌组织中的表达明显高于Ⅰ、Ⅱ期(P=0.029),G3级表达显著高于G1、G2级(P=0.006),但不同病理类型比较,差异无统计学意义(P0.05)。结论 OPN表达上调与卵巢癌紫杉醇化疗耐药有一定相关性,且与肿瘤临床分期、病理分级密切相关。
[Abstract]:Objective to investigate the relationship between osteopontinin (OPN) and paclitaxel resistance in ovarian cancer and its clinical significance. Methods 72 cases of ovarian epithelial carcinoma were collected from March to October 2013 in several third Class A hospitals in Beijing. According to the in vitro drug sensitivity test of adenosine triphosphate tumor, it was divided into paclitaxel sensitive group (49 cases) and moderately sensitive group (15 cases) and drug-resistant group (8 cases). Western blot was used to detect the expression of OPN in each group. The expression of OPN in the drug group (2.027 卤0.402) was significantly higher than that in the sensitive group (0.603 卤0.271) and the mild sensitive group (1.173 卤0.350). There was a positive correlation between the expression of OPN and the sensitivity coefficient of paclitaxel. The expression of OPN in stage 鈪，

本文编号：1660438